Infliximab Improves Quality of Life in UC Regardless of Baseline Disease Activity
Brian G. Feagan(Western University), Bruce E. Sands(Icahn School of Medicine at Mount Sinai), William J. Sandborn(University of San Diego), M Bala, P. Rutgeerts, S. B. Hanauer(University of Chicago), Walter Reinisch(Medical University of Vienna), S. Yan, D. Eisenberg, Jewel Johanns(Johnson & Johnson (United States)), A. Olson
Cited by 0
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment
|Genome biology|2012|2.8k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k